Santiago Gisler,  —

Early viral infections cause inflammation and bacterial infections in the lower airway of the lungs of infants with cystic fibrosis (CF), according to a study. The prospective study, “Early respiratory viral infections in infants with cystic fibrosis,” was published in the Journal of Cystic Fibrosis. Although bacterial infections…

Researchers at Case Western Reserve University School of Medicine have received a $3.34 million grant from the National Institutes of Health (NIH) to develop a new strategy to sensitize Burkholderia multivorans — a common pathogen in patients with lung diseases like cystic fibrosis (CF) — to the action of…

Exposing cystic fibrosis (CF) patients to high levels of oxygen through hyperbaric oxygen treatment may make Pseudomonas aeruginosa bacterial aggregates more sensitive to antibiotics like tobramycin and easier to eradicate from the lungs, a study in patient-derived bacterial cultures reports. The study, “Hyperbaric oxygen treatment increases killing of aggregating Pseudomonas aeruginosa isolates from…

SQI Diagnostics announced two new research agreements with research hospital University Health Network (UHN), Toronto, Canada, to simplify the assessment of lungs for transplant. By creating and licensing multiplexed protein assays and point-of-care diagnostic strategies, they intend to improve the health of donor organs so they can be transplanted safely…

Patients with cystic fibrosis (CF) whose lungs have never been colonized by the Pseudomonas aeruginosa bacterium have a  milder form of the disease, a retrospective study based on registry data suggests. The study, “Clinical and microbiological characteristics of cystic fibrosis adults never colonized by Pseudomonas aeruginosa: Analysis of the French…

Sound Pharmaceuticals (SPI) has enrolled its first-patient-in — meaning the first subject meeting the criteria for inclusion and exclusion of a clinical study — in a Phase 2 trial testing SPI-1005 for the prevention and treatment of tobramycin-induced ototoxicity in cystic fibrosis (CF) patients, the company announced. Tobramycin…

AzurRx BioPharma announced it has started a Phase 2 clinical trial testing the safety, tolerability, and efficacy of MS1819 Spray Dried (MS1819-SD) therapy in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI). The trial was approved in October by the U.S. Food and Drug Administration. Many…

Researchers tested blood samples from cystic fibrosis (CF) patients and identified distinct gene expression patterns that could lead to patient-tailored treatments, a study reports. The study, “Identification of molecular signatures of cystic fibrosis disease status using plasma-based functional genomics,” was published in Physiological Genomics. To better understand…

Vast Therapeutics announced that it received funding from the Cystic Fibrosis Foundation (CFF) to support further development of BIOC51, the company’s investigative treatment for antibiotic-resistant bacteria, including Pseudomonas aeruginosa, that is often the cause of lung infections in cystic fibrosis (CF) patients. P. aeruginosa infections set in when mucus accumulation…

A recent study confirmed the presence of increased serum levels of interleukin-7 (IL-7) in cystic fibrosis (CF) patients, compared with healthy controls. The researchers could establish a link between higher IL-7 levels and worse lung function in patients, suggesting a possible biomarker for CF. The study, “Higher…